Hope for kids with rare brain cancer: new drug combo trial launches
NCT ID NCT07447076
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, gemcitabine and paxalisib, in children, teens, and young adults whose atypical teratoid rhabdoid tumor (ATRT) has come back or gotten worse. The goal is to find a safe dose and see if the drugs can control the tumor. About 29 participants will receive the drugs and undergo regular scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and paxalisib
- What this could lead to
- If this works, it could offer a new treatment option to control recurrent ATRT brain tumors in children and young adults.
- What could go wrong
- This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The drug combo may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR (ATRT) OF THE CNS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.